Key result
Dietary simvastatin at 20 or /kg/day for 6-12 weeks did not decrease VLCFA content in ALD mouse tissues, and increased brain VLCFA at /kg/day.
Why the study?
Does simvastatin reduce very long chain fatty acid content in tissues of adrenoleukodystrophy mice?
Does simvastatin reduce very long chain fatty acid content in tissues of adrenoleukodystrophy mice?
Simvastatin does not normalize very long chain fatty acids in ALD mice and may even increase them in the brain at high doses, contrasting with its effects in human fibroblasts and plasma.
Answers are grounded in this paper and cite their sources.
Does not support simvastatin for VLCFA reduction in ALD; leaves open whether other statins or models warrant further testing.
X-linked adrenoleukodystrophy (ALD) is a genetic demyelinating disorder characterized by accumulation of very long chain fatty acid (VLCFA) in tissues. Lovastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, normalizes VLCFA in fibroblasts and plasma from ALD patients. We dietary treated ALD mice with simvastatin, an analog of lovastatin with similar pharmacokinetics and effects on plasma VLCFA in ALD patients at 20 or 60 mg/kg/day for 6-12 weeks. No decrease of VLCFA content was observed in mouse tissues, including the brain. A significant increase of VLCFA was rather observed in the brain of ALD mice at 60 mg/kg/day.
No takes yet. Share an insight, caveat, or question.
Cartier et al. (2000) studied X-linked adrenoleukodystrophy (ALD). Simvastatin was evaluated on Very long chain fatty acid (VLCFA) content in tissues. Dietary simvastatin at 20 or /kg/day for 6-12 weeks did not decrease VLCFA content in ALD mouse tissues, and increased brain VLCFA at /kg/day.
Synapse has enriched 10 related papers. Consider them for comparative context: